EZH2, an epigenetic driver of prostate cancer.
EZH2, an epigenetic driver of prostate cancer.
复制标题
DOI：
10.1007/s13238-013-2093-2
复制
发表时间：
2013-05
期刊：
影响因子：
21.1
通讯作者：
Yu J
中科院分区：
文献类型：
--
作者：
Yang YA;Yu J
The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.
登录
查看更多内容
影响因子：
50.3
作者：
Chang CJ;Yang JY;Xia W;Chen CT;Xie X;Chao CH;Woodward WA;Hsu JM;Hortobagyi GN;Hung MC
通讯作者：
Hung MC
影响因子：
1.6
作者：
Arisan, S;Buyuktuncer, ED;Ergenekon, E
通讯作者：
Ergenekon, E
影响因子：
11.5
作者：
Chase, Andrew;Cross, Nicholas C. P.
通讯作者：
Cross, Nicholas C. P.
影响因子：
64.5
作者：
Czermin, B;Melfi, R;Pirrotta, V
通讯作者：
Pirrotta, V
影响因子：
2.7
作者：
Chang, Fang-Rong;Hwang, Tsong-Long;Wu, Yang-Chang
通讯作者：
Wu, Yang-Chang